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Abstract Objective: To examine trends in prescribing of
angiotensin II receptor blockers (ARBs) as initial and
second-line treatment of hypertension.
Methods: We performed a cohort study in the Integrated
Primary Care Information database, a general practice
research database in The Netherlands. We included
hypertensive patients who were newly treated with
antihypertensive drugs between 1996 and 1999. Initial
treatment was deﬁned as the ﬁrst prescribed antihyper-
tensive drug after diagnosis of hypertension. As second-
line treatment, we considered prescriptions of a second
antihypertensive drug class, either as switch or addition.
We used logistic regression and Cox proportional haz-
ard analysis to estimate time trends in use of ARBs as
initial or second-line treatment.
Results: In total, 8% of the 3,102 newly treated hyper-
tensive patients received ARBs as initial treatment. Ini-
tial ARB use increased signiﬁcantly from 4% to 10%
during the period 1996–1999, whereas calcium channel
blocker and angiotensin-converting enzyme inhibitor
(ACE-I) use decreased. ARBs were used as second-line
treatment in less than 4% of 2,544 patients who were
initially treated with an antihypertensive drug other than
an ARB: 2% switched to an ARB (mostly from ACE-Is)
and 1% received ARBs as add-on treatment. Diuretics
and beta-blockers were used ﬁve to ten times more often
as add-on treatment than ARBs.
Conclusion: ARBs achieved a position in the treatment of
hypertension as initial rather than second-line therapy.
Introduction
Angiotensin II receptor blockers (ARBs) form the new-
est class of antihypertensive agents, which have been
available in The Netherlands since 1995. Their eﬃcacy in
lowering blood pressure is comparable to other antihy-
pertensive drug classes, but they are suggested to be
better tolerated and therefore are an attractive option for
the treatment of hypertension [1–3]. During the ﬁrst
years after their introduction, however, there was no
evidence from large clinical trials of their beneﬁts on
cardiovascular morbidity and mortality. In 2001, bene-
ﬁts of ARBs were demonstrated in patients with heart
failure, and in hypertensive patients with coexisting
diabetes, proteinuria or microalbuminuria [4–7]. The
ﬁrst clinical trial looking at hard endpoints in a large
group of patients with essential hypertension was pub-
lished in 2002 [8]. Recently, doubts were raised regarding
long-term safety of ARBs [9]. Therefore, in most na-
tional and international hypertension guidelines, ARBs
have no place as initial treatment in hypertension and are
only recommended as second-line treatment in patients
who require angiotensin-converting enzyme inhibitors
(ACE-Is) but do not tolerate them [10, 11]. Patients for
whom ACE-Is are preferred are those with coexisting
heart failure, diabetes, proteinuria or renal insuﬃciency.
Several studies have shown the discrepancy between
prescribing patterns in hypertension and guideline rec-
ommendations [12–14]. These studies did not include
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ARBs as (separate) drug class. Also, studies describing
initial and second-line use of antihypertensive drugs did
not provide speciﬁc information on ARB use [15–17].
Recently, it was shown that prescribing of ARBs in-
creased rapidly in the late 1990s, but it is unclear to what
extent this involved initial or second-line therapy for
hypertension [18, 19].
The objective of this study was to examine trends in
prescribing of ARBs as initial and second-line treatment




We used data from the Integrated Primary Care Infor-
mation (IPCI) database from the Erasmus Medical
Center in The Netherlands. This is a longitudinal general
practice research database containing the complete
electronic medical records from more than 100 partici-
pating Dutch general practitioners (GPs). The electronic
records contain coded and anonymous data on patient
demographics, symptoms (in free text), diagnoses (using
the International Classiﬁcation for Primary Care [20] and
free text), laboratory ﬁndings, referrals and drug pre-
scriptions. To maximise completeness of the data, GPs
who contribute to the IPCI database are not permitted to
use paper-based records. The database complies with
European Union guidelines on the use of medical data
for medical research and has been proven valid for
pharmaco-epidemiological research in several studies
that evaluated the quality of the available data [21].
Study period and population
In this cohort study, we included patients with a diag-
nosis of hypertension who were newly treated with
antihypertensive drugs between 1 January 1996 and 31
December 1999, following the introduction of the ﬁrst
ARB on the Dutch market in March 1995. Hypertension
was deﬁned as a coded diagnosis of hypertension (ICPC:
K85, K86, K87) [20] or a free text listing of hypertension
in the patient record. This latter group was manually
evaluated to include only those patients for whom
hypertension was mentioned as their diagnosis. Patients
were excluded if they already had received antihyper-
tensive drugs in the 6 months preceding their diagnosis
of hypertension.
Deﬁnitions of initial and second-line treatments
As initial treatment, the ﬁrst prescription of antihyper-
tensive drug therapy within the 6 months after diagnosis
of hypertension was classiﬁed as a diuretic, beta-blocker,
calcium channel blocker, ACE-I, ARB or combination
of these (ﬁxed or co-administered). The course of anti-
hypertensive therapy was followed for 1 year to deter-
mine which second-line treatment was started after
initial monotherapy. Second-line treatment was deﬁned
as the second step in the treatment strategy, which can
consist of a switch to or an addition of a diﬀerent
antihypertensive drug class. We chose a follow-up peri-
od of 1 year, because most changes in antihypertensive
treatment occur during the ﬁrst year of treatment [22].
To characterize the course of treatment, four mutually
exclusive categories were distinguished depending on the
timing and type of subsequent antihypertensive drug
prescriptions: continuation, discontinuation, switch or
add-on treatment. Continuation was deﬁned as receiving
a repeat prescription for the initial drug class at least
every 6 months and no prescription for any other anti-
hypertensive drug class during follow-up. Discontinua-
tion was deﬁned as having no prescription for any
antihypertensive drug class during the 6 months fol-
lowing the date of the last prescription of the initial drug
class. A switch in treatment was considered if an alter-
native antihypertensive drug class was prescribed within
6 months after a discontinuation of the initial drug class.
Add-on treatment was deﬁned as receiving a prescription
for a diﬀerent antihypertensive drug class in addition to
a prescription of the initial drug class, simultaneously or
in the following 3 months.
Data analyses
A descriptive analysis characterized the study popula-
tion and deﬁned subgroups according to calendar year
and type of initial antihypertensive drug treatment.
Diﬀerences in patient characteristics between year co-
horts were tested using chi-square tests. To assess whe-
ther the initial treatment changed over the study years,
odds ratios for calendar year were estimated using lo-
gistic regression analysis adjusting for age and sex.
Separate models were run for each antihypertensive drug
class. To compare second-line treatment in diﬀerent year
cohorts, Cox proportional hazard analysis was used to
calculate age- and sex-adjusted hazard ratios for each
drug class. This analysis takes possible diﬀerences in
follow-up time into account. Subgroup analyses were
conducted excluding patients with prevalent comorbid
conditions that may aﬀect ARB use, i.e. heart failure,
diabetes, proteinuria and/or renal insuﬃciency.
Results
We identiﬁed 3,102 hypertensive patients who received
an initial antihypertensive treatment. Patients had a
mean age of 58 years and 58% were female (Table 1).
Patients who started antihypertensive treatment later
during the study period were somewhat younger (v2-test
P=0.153). The proportion of male patients increased
signiﬁcantly from 37% in 1996 to 45% in 1999 (v2-test
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P=0.017). Hypertensive patients with heart failure,
diabetes, proteinuria and/or renal insuﬃciency repre-
sented 14% of the study population.
Initial antihypertensive treatment
Initial use of each antihypertensive drug class diﬀered
between various patient subgroups, e.g. by sex and age
(Table 1). Examination of time trends of initial antihy-
pertensive treatment demonstrated marked changes be-
tween 1996 and 1999: the percentage of ARBs as initial
treatment increased from 4% to 10%, diuretics in-
creased from 18% to 25%, whereas use of calcium
channel blockers fell from 12% to 6% and ACE-Is from
23% to 18%. These time trends remained signiﬁcant
after adjustment for sex and age (Table 2). Initial use of
beta-blockers remained stable over the years (31%).
Also, initial use of combination therapy remained stable,
but there was a signiﬁcant increase of combination
therapies consisting of ARBs (from 0.2% to 2%).
Restriction of the analyses to hypertensive patients
without heart failure, diabetes, proteinuria and/or renal
insuﬃciency showed similar time trends in initial use of
ARBs (data not shown).
During the ﬁrst year of follow-up, 31% of patients
continued their initial treatment, 30% discontinued
treatment, 12% switched therapy, 19% received add-on
therapy and 8% did not have 1 year of follow-up
(Table 3). Initial users of ARBs discontinued treatment




according to sex, age and year
cohort. CCB calcium channel
blocker, ACE-I angiotensin-
converting enzyme inhibitor,
ARB angiotensin II receptor
blocker
a Percentages of row total;















Male 1,293 (42) 12.8 33.3 10.1 23.7 8.7 11.3
Female 1,809 (58) 26.6 31.1 8.3 17.5 6.7 9.8
Age (years)
18–49 842 (27) 16.6 43.0 6.2 21.5 6.8 5.9
50–59 780 (25) 17.8 38.8 7.6 18.5 7.3 10.0
60–69 676 (22) 20.1 26.9 10.4 21.2 9.8 11.7
70–79 586 (19) 26.8 19.6 12.5 20.1 7.0 14.0
80+ 218 (7) 34.4 14.2 12.4 17.0 6.0 16.1
Year cohort
1996 550 (18) 18.2 31.3 11.6 23.1 3.8 12.0
1997 670 (22) 17.2 32.4 12.7 21.3 7.0 9.4
1998 858 (28) 20.3 33.2 8.3 19.8 7.6 10.8
1999 1,024 (33) 25.2 31.2 6.0 17.9 9.9 10.0
Table 2 Time trends in the initial use of diﬀerent antihypertensive
drug classes in 3,102 hypertensive patients. Odds ratios for calendar
year were adjusted for sex and age. Separate models were run for
each antihypertensive drug class. CCB calcium channel blocker,
ACE-I angiotensin-converting enzyme inhibitor, ARB angiotensin
II receptor blocker
Table 3 Treatment after 1 year in patients who were initially
treated with antihypertensive monotherapy. DIU diuretic, BB beta-
blocker, CCB calcium channel blocker, ACE-I angiotensin-con-
verting enzyme inhibitor, ARB angiotensin II receptor blocker. P
values refer to comparisons between patient groups who initially
received diﬀerent antihypertensive drug classes (ANOVA)
Adjusted odds ratios (95% conﬁdence interval)
1996 1997 1998 1999
Diuretics 1 (reference) 1.0 (0.7–1.3) 1.2 (0.9–1.6) 1.7* (1.3–2.2)
Beta-blockers 1 (reference) 1.0 (0.8–1.3) 1.1 (0.8–1.3) 0.9 (0.7–1.2)
CCBs 1 (reference) 1.1 (0.8–1.6) 0.7* (0.5–1.0) 0.5* (0.3–0.7)
ACE-Is 1 (reference) 0.9 (0.7–1.2) 0.8 (0.6–1.0) 0.7 (0.5–0.9)
ARBs 1 (reference) 1.9* (1.1–3.2) 2.0* (1.2–3.3) 2.7* (1.7–4.4)
Combination therapy 1 (reference) 0.8 (0.5–1.1) 0.9 (0.6–1.3) 0.8 (0.6–1.2)
*Signiﬁcant at P<0.05 level
Initial antihypertensive drug treatment
DIU n (%) BB n (%) CCB n (%) ACE-I n (%) ARB n (%) Total n (%) P value
Patients (total) 647 993 281 623 234 2778
Continuation 150 (23) 341 (34) 91 (32) 185 (30) 83 (35) 850 (31) <0.001
Discontinuation 255 (39) 290 (29) 83 (30) 162 (26) 52 (22) 842 (30) <0.001
Switch 83 (13) 87 (9) 48 (17) 96 (15) 22 (9) 336 (12) <0.001
Add-on 102 (16) 191 (19) 38 (14) 131 (21) 59 (25) 521 (19) 0.002
Incomplete follow-up 57 (9) 84 (8) 21 (7) 49 (8) 18 (8) 229 (8) 0.943
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less frequently (22%) than those who started on
diuretics (39%), beta-blockers (29%), calcium channel
blockers (30%) or ACE-Is (26%). Initial users of ARBs
had a slightly lower proportion of switches, but received
somewhat more add-on therapies than initial users of
other antihypertensive drug classes (Table 3).
Second-line antihypertensive treatment
Of the 2,544 patients who were initially treated with an
antihypertensive drug other than an ARB, 59 patients
switched to ARBs (2.3%). This rate is comparable to the
percentages of switches to diuretics and calcium channel
blockers (Table 4). Switches to beta-blockers (5.4% of
patients starting on another drug) and ACE-Is (4.3%)
occurred about twice as often. Of the 59 switches to an
ARB, 32 originated from initial ACE-I use (54%).
Hypertensive patients without heart failure, diabetes,
proteinuria and/or renal insuﬃciency switched just as
much to ARBs (on average 2.4%) as patients with these
comorbidities. Percentage of switches to ARBs increased
signiﬁcantly from 1.1% in 1996 to 3.0% in 1997, but
decreased again to 1.7% in 1999. The same pattern was
observed in the Cox regression analysis when we ac-
counted for variable follow-up time (Table 5).
Of the 2,544 patients who were initially treated with
an antihypertensive drug other than an ARB, 36 patients
received ARBs as add-on treatment (1.4%). Hyperten-
sive patients without heart failure, diabetes, proteinuria
and/or renal insuﬃciency received comparable percent-
ages of ARBs as add-on treatment (1.3%). Add-on
therapies with other drug classes were far more common
than with ARBs, especially the addition of diuretics
(11.7% of patients starting on another drug) and beta-
blockers (6.5%). The percentage of add-on treatment
with ARBs increased gradually from 0.4% in 1996 to
2.2% in 1999; patients in cohort 1999 received ARBs
signiﬁcantly more often as add-on treatment than those
in 1996 (Table 6).
Discussion
This study provides an overview of the uptake of ARBs
in the treatment of hypertension in The Netherlands.
Initial use of ARBs increased substantially in the years
following their introduction, mostly at the expense of
calcium channel blockers and ACE-Is. The use of ARBs
as second-line treatment was much lower. In 1999, more
than 10% of the newly treated hypertensive patients
received an ARB as initial treatment, whereas less than
Table 4 Second-line treatment choice: switches and add-on therapy. DIU diuretic, BB beta-blocker, CCB calcium channel blocker, ACE-I
angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker
Initial antihypertensive drug treatment
DIU n (%) BB n (%) CCB n (%) ACE-I n (%) ARB n (%) Total n (%)
Switch (total)a 83 (13) 87 (9) 48 (17) 96 (15) 22 (9) 336 (12)
to DIU – 16 (2) 12 (4) 14 (2) 7 (3) 49 (2)
to BB 35 (5) – 20 (7) 32 (5) 10 (4) 97 (5)
to CCB 12 (2) 17 (2) – 19 (3) 3 (1) 51 (2)
to ACE-I 28 (4) 44 (4) 17 (6) – 3 (1) 92 (4)
to ARB 8 (1) 15 (2) 4 (1) 32 (5) – 59 (2)
Add-on (total)a 102 (16) 191 (19) 38 (14) 131 (21) 59 (25) 521 (19)
with DIU – 121 (12) 14 (5) 76 (12) 39 (17) 250 (12)
with BB 56 (9) – 16 (6) 30 (5) 14 (6) 116 (6)
with CCB 7 (1) 34 (3) – 18 (3) 5 (2) 64 (3)
with ACE-I 33 (5) 30 (3) 6 (2) – 1 (0) 70 (3)
with ARB 10 (2) 11 (1) 3 (1) 12 (2) – 36 (1)
a Switches or add-on therapies to combinations of two diﬀerent antihypertensive drug classes are counted in both classes (n=27).
Therefore, the numbers in each column may add up to more than the total of switches or add-on therapies
Table 5 Time trends in second-line treatment of diﬀerent antihy-
pertensive drug classes due to a treatment switch. Hazard ratios for
calendar year were adjusted for sex and age. Separate models were
run for each of the ﬁve drug classes. CCB calcium channel blocker,
ACE-I angiotensin-converting enzyme inhibitor, ARB angiotensin
II receptor blocker
Adjusted hazard ratios (95% conﬁdence interval)
1996 1997 1998 1999
Diuretics 1 (reference) 1.7 (0.7–4.5) 1.6 (0.6–4.2) 1.8 (0.7–4.6)
Beta-blockers 1 (reference) 0.8 (0.4–1.6) 1.0 (0.6–1.9) 1.1 (0.6–2.0)
CCBs 1 (reference) 1.7 (0.7–4.0) 0.8 (0.3–2.0) 1.0 (0.4–2.4)
ACE-Is 1 (reference) 0.7 (0.4–1.3) 0.6 (0.3–1.0) 0.6 (0.3–1.0)
ARBs 1 (reference) 2.8* (1.0–7.5) 3.0* (1.2–8.0) 1.6 (0.6–4.5)
*Signiﬁcant at P<0.05 level
464
4% of all patients who were initially treated with an-
other antihypertensive drug received an ARB as second-
line therapy in the following year. Switching to an ARB
occurred slightly more often than the addition of an
ARB as second-line treatment, but we did observe an
increasing rate of add-on treatments with ARBs by the
year 1999. Patients who switched to ARBs mostly came
from initial treatment with an ACE-I. Beta-blockers and
diuretics remained the most common initial and second-
line treatment choice in The Netherlands.
If guideline recommendations had been followed
during our study period, one would have expected ARBs
to be prescribed mostly as second-line treatment, espe-
cially in patients unable to tolerate ACE-Is [10, 11].
Contrary to these expectations, ARBs were not very
popular as second-line treatment, but instead achieved a
signiﬁcant position as initial treatment for hypertension.
As we reported elsewhere, this position was not re-
stricted to patients with relevant comorbidities [19].
ARBs were already used as initial treatment in uncom-
plicated hypertensive patients before trials on cardio-
vascular endpoints became available. A previous study
indicated a similar pattern regarding ACE-Is shortly
after their introduction [12]. While the prescribing of
ACE-Is seems to have developed into a pattern that is
more in accordance with guideline recommendations
[19], this appears not (yet) to be the case for the ARBs.
Studies showing that ARBs are better tolerated and
have higher persistence rates than other antihypertensive
drug classes probably encouraged prescribing of these
newer drugs as the initial treatment [25, 26]. It is likely
that promotional activities of the pharmaceutical
industry accelerated the dissemination and adoption of
these views [27]. Pharmaceutical companies in The
Netherlands devoted substantial resources to promote
the advantages of ARBs in terms of eﬃcacy and toler-
ability [28]. For pharmaceutical companies, there was a
lot at stake when patents of a number of antihyperten-
sive drugs, mainly ACE-Is, expired. For GPs, however,
there were no restrictions to prescribe the newer, more
expensive drugs nor incentives to prescribe generic drugs
at that time.
Another factor in the uptake of new drugs concerns
the inﬂuence of specialists. Especially for cardiovascular
drugs, a substantial impact has been observed on the
GPs’ prescribing [29]. In The Netherlands, prescriptions
initiated by specialists are often continued by GPs. This
obviously aﬀects the prevalent use of ARBs in general
practice [19]. In this study, however, we looked at ﬁrst
prescriptions within 6 months after a diagnosis of
hypertension. These will mostly be prescriptions initi-
ated by the GPs themselves. Moreover, the rapid in-
crease in the use of ARBs immediately after their
introduction on the market also suggests that GPs have
started to prescribe these drugs on their own initiative.
The increased initial treatment with ARBs occurred
at the expense of calcium channel blockers and ACE-Is.
The debate on controversial results regarding the safety
of calcium channel blockers around 1996 may have
played a role in the decreased prescribing of calcium
channel blockers [30]. The increased rate of ARBs as
add-on therapy may be a result of an intensiﬁed treat-
ment of hypertension. Guidelines recommend the addi-
tion of a second drug from a diﬀerent class when
adequate blood pressure levels are not achieved. How-
ever, only one in every ﬁve patients received an add-on
therapy in the ﬁrst year of treatment. This conﬁrms the
ﬁndings from previous studies showing that hyperten-
sion is undertreated in The Netherlands [23, 24].
Moreover, 30% of all newly treated patients discontin-
ued treatment in the ﬁrst year, which is similar to results
from other studies [15–17]. This implies that there is still
much room for improvement in hypertension treatment.
This is the ﬁrst study that focused on the uptake of
ARBs in the treatment of hypertension, and made a
distinction between initial and second-line treatment.
Other studies which described prescribing patterns of
initial and second-line antihypertensive drugs gave no
clear information on ARB use [15–17]. A strength of this
study is that we used routinely collected data from a
large, longitudinal general practice database comprising
information about diagnosis and prescriptions at the
patient level. This allowed us to follow dynamics in
prescribing patterns in cohorts of individual newly
treated hypertensive patients in the years following the
introduction of ARBs. A limitation of this study lies in
our deﬁnitions of initial and second-line treatment. We
identiﬁed changes in treatment in a period of 6 months,
which is a commonly used time window. This covers
twice the maximum period of 3 months that may be
Table 6 Time trends in second-line treatment of diﬀerent antihy-
pertensive drug classes due to add-on treatment. CCB calcium
channel blocker, ACE-I angiotensin-converting enzyme inhibitor,
ARB angiotensin II receptor blocker. Hazard ratios for calendar
year were adjusted for sex and age. Separate models were run for
each of the ﬁve drug classes
Adjusted hazard ratios (95% conﬁdence interval)
1996 1997 1998 1999
Diuretics 1 (reference) 1.3 (0.9–1.9) 1.2 (0.8–1.8) 1.1 (0.7–1.6)
Beta-blockers 1 (reference) 1.1 (0.6–2.2) 1.7 (0.9–3.2) 1.7 (0.9–3.1)
CCBs 1 (reference) 0.8 (0.3–2.0) 1.2 (0.5–2.5) 1.2 (0.6–2.6)
ACE-Is 1 (reference) 1.3 (0.6–2.9) 1.1 (0.5–2.4) 1.3 (0.6–2.7)
ARBs 1 (reference) 3.3 (0.7–15.6) 2.7 (0.6–12.8) 5.5* (1.3–23.6)
*Signiﬁcant at P<0.05 level
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supplied by one prescription for antihypertensive drugs
in The Netherlands.
Although this study focused on the uptake of ARBs,
it may have implications for understanding the adoption
process of other new therapeutic drug classes. It appears
that newer, more expensive drug classes are chosen soon
after their introduction on the market, not primarily for
patients who do not respond satisfactorily to previous
treatment, but often in newly treated patients without
speciﬁc reasons. Since beneﬁts on hard endpoints are
often not established and also long-term risks are not
known, this may have important consequences on health
care.
In conclusion, ARBs have achieved a position in the
treatment of hypertension as initial rather than second-
line therapy which is not in accordance with the existing
guideline recommendations for hypertension.
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